Can I Take St. John's Wort with Vyvanse?

What Is the Interaction Between St. John's Wort and Vyvanse?

The combination produces two separate and additive hazards. First, St. John's Wort is a well-characterized inducer of CYP3A4, CYP2C9, and the drug-transporter P-glycoprotein, which together can lower plasma concentrations of many co-administered medications. Second, both agents increase synaptic serotonin availability through distinct mechanisms, creating a pharmacodynamic risk for serotonin toxicity even when blood levels of lisdexamfetamine appear normal.

Why CYP3A4 Matters for Lisdexamfetamine

Vyvanse itself is a prodrug. After oral ingestion, lisdexamfetamine is hydrolyzed in red blood cells to the active compound d-amphetamine. While amphetamine metabolism primarily involves monoamine oxidase (MAO) and CYP2D6, CYP3A4 contributes a secondary but meaningful oxidative pathway. Research published in the journal Drug Metabolism and Disposition confirms that CYP3A4 participates in amphetamine N-oxidation, particularly at higher substrate concentrations [1]. Induction of this pathway by hypericin and hyperforin (the active constituents of St. John's Wort) can accelerate d-amphetamine clearance, potentially shortening duration of effect and reducing peak plasma levels.

The FDA's drug interaction guidance recognizes hypericum perforatum as a clinically significant CYP3A4 inducer [2]. A landmark 2000 study in The Lancet by Piscitelli et al. (N=8 healthy volunteers) showed that St. John's Wort reduced indinavir AUC by 57%, illustrating how aggressively this herb can strip circulating drug levels [3].

The P-Glycoprotein Component

P-glycoprotein (P-gp) is an efflux transporter expressed in the gut wall and blood-brain barrier. St. John's Wort upregulates P-gp expression through pregnane X receptor (PXR) activation [4]. For amphetamine compounds, P-gp upregulation in the gut could reduce net absorption. At the blood-brain barrier, it might limit CNS entry of the active metabolite. A 2003 study in Clinical Pharmacology and Therapeutics by Dresser et al. Documented SJW-mediated P-gp induction reducing digoxin AUC by 25% in healthy subjects [5]. While amphetamine is not as definitively a P-gp substrate as digoxin, the mechanism warrants concern given the narrow therapeutic index of stimulant medications.

Pharmacodynamic Serotonin Risk

Amphetamines trigger serotonin release from presynaptic terminals in addition to their primary dopamine and norepinephrine activity [6]. St. John's Wort inhibits synaptic reuptake of serotonin, dopamine, and norepinephrine via a mechanism similar to, but weaker than, tricyclic antidepressants [7]. Combining the two creates additive serotonergic stimulation. A 2016 systematic review in CNS Drugs by Nicolussi et al. Catalogued 28 case reports of clinically significant interactions between St. John's Wort and serotonergic drugs, with symptoms ranging from mild tremor and agitation to frank serotonin syndrome [8].

The Hunter Serotonin Toxicity Criteria define serotonin syndrome by the triad of neuromuscular abnormalities, autonomic instability, and altered mental status. Mild presentations can be mistaken for ADHD symptom breakthrough or anxiety, creating a diagnostic delay that worsens outcomes [9].

How Significant Is the Risk in Practice?

The magnitude of the pharmacokinetic effect depends on St. John's Wort dose, standardization of hypericin/hyperforin content, and duration of use. Not every product on the market is equivalent.

Dose and Standardization Variability

Commercial SJW preparations vary widely. A 2016 analysis in Planta Medica found that hyperforin content across 35 retail products ranged from 0.01% to 6.7%, a more than 600-fold difference [10]. Because hyperforin is the primary PXR ligand responsible for CYP3A4 induction, low-hyperforin extracts carry a lower (but not zero) induction risk. Patients sourcing SJW from online retailers or health food stores rarely know the standardization of their product. This unpredictability makes it impossible to define a "safe" SJW dose alongside Vyvanse.

Timeline of Induction and Washout

CYP3A4 induction requires new enzyme synthesis and typically reaches clinically meaningful levels after 7 to 14 days of daily SJW exposure. The effect reverses within approximately 14 days after SJW discontinuation as existing enzyme is degraded [11]. This means a person who begins SJW may notice their Vyvanse feeling weaker over the first two weeks, while someone stopping SJW abruptly might experience a sudden increase in amphetamine plasma levels that feels like an overdose.

Who Is at Highest Risk for Serotonin Toxicity?

Patients on Vyvanse who also use any of the following agents alongside SJW face compounding serotonergic load: SSRIs, SNRIs, bupropion, tramadol, triptans, or linezolid. According to the 2005 guidelines from the American College of Emergency Physicians on serotonin toxicity, the risk scales with the number and potency of serotonergic agents in use simultaneously [9]. Adding SJW to an already complex regimen that includes a stimulant is therefore riskiest in polypharmacy contexts.

What Does the Evidence Say About St. John's Wort for ADHD?

Some patients consider SJW for ADHD because older, small studies suggested mood and attention benefits. The controlled data do not support this use.

The Weber et al. Trial

A 2008 randomized controlled trial by Weber et al. Published in the Journal of Child and Adolescent Psychopharmacology (N=54 children, 8 weeks) found no statistically significant difference between St. John's Wort and placebo on the Conners' Parent Rating Scale ADHD subscale (P=0.47) [12]. This is the best-quality RCT data available for SJW in ADHD, and it shows no benefit.

Contrast With Approved Therapies

The 2019 American Academy of Pediatrics ADHD clinical practice guideline states that stimulant medications achieve response rates of 70% to 80% in children and adolescents with ADHD, with lisdexamfetamine (Vyvanse) supported by Phase III data demonstrating statistically significant improvements on the ADHD-RS-IV scale versus placebo [13]. The gap between SJW's null RCT result and the strong efficacy data for lisdexamfetamine is large.

What to Do If You Are Already Taking Both

Do not stop either agent abruptly without speaking to your prescriber first.

Stopping St. John's Wort Suddenly

Abrupt SJW discontinuation removes the CYP3A4 induction within roughly 14 days. If the Vyvanse dose had been increased by a prescriber to compensate for reduced efficacy (without knowing SJW was the cause), stopping SJW could result in supra-therapeutic amphetamine levels. Symptoms of amphetamine excess include tachycardia, hypertension, insomnia, and anxiety.

Monitoring Parameters

Your prescriber should check the following if you disclose concurrent SJW use:

• Resting heart rate and blood pressure at the next visit
• Sleep quality and appetite, both sensitive early markers of amphetamine over-exposure
• Presence of any serotonergic symptoms: tremor, diaphoresis, myoclonus, or hyperreflexia
• Current Vyvanse dose relative to symptom control since starting SJW

Tapering and Transition Plan

A reasonable clinical approach involves stopping SJW with a gradual taper over 1 to 2 weeks (if the patient has been on it for more than 4 weeks) to reduce the rebound induction reversal effect, followed by reassessment of Vyvanse efficacy at week 2 to 3 post-discontinuation. Any dose adjustment to Vyvanse should occur only after the induction washout period is complete.

Safer Supplement Options Alongside Vyvanse

Patients seeking adjunctive nutritional support for ADHD symptoms have several better-tolerated options with no significant Vyvanse interaction risk.

Omega-3 Fatty Acids

A 2018 meta-analysis in Neuropsychopharmacology by Chang et al. (14 RCTs, N=1,692) found that omega-3 supplementation produced a small but statistically significant improvement in ADHD symptoms (standardized mean difference 0.38, P<0.001) [14]. No clinically meaningful pharmacokinetic interaction with amphetamine compounds has been identified for fish oil.

Zinc

Zinc deficiency is more prevalent in children with ADHD than in controls, and a 2011 RCT by Bilici et al. (N=202) showed zinc sulfate 150 mg/day over 12 weeks improved hyperactivity-impulsivity scores versus placebo [15]. Zinc does not induce or inhibit CYP3A4.

Magnesium

Low magnesium status has been associated with ADHD symptom severity in observational studies. Magnesium glycinate or threonate does not carry significant CYP450 interactions and is generally well tolerated at doses of 200 to 400 mg/day in adults [16].

The table below summarizes the interaction profile of common supplements considered by patients on Vyvanse. This framework is intended as a clinical reference for prescribers and patients during shared decision-making conversations.

| Supplement | CYP3A4 Effect | Serotonergic Effect | Recommended with Vyvanse? | |---|---|---|---| | St. John's Wort | Strong inducer | Moderate (reuptake inhibition) | No | | Omega-3 (fish oil) | None known | None | Yes, with prescriber awareness | | Zinc | None | None | Yes | | Magnesium | None | None | Yes | | Valerian root | Weak CYP3A4 inhibitor (in vitro) | None | Caution, limited data | | 5-HTP | None known | Moderate to strong | No (serotonin risk) | | Rhodiola rosea | Possible MAO inhibition | Low | Caution |

What Clinicians and Guidelines Say

The prescribing information for Vyvanse (lisdexamfetamine dimesylate) states: "Amphetamines should not be used with serotonergic drugs. Combination of amphetamine with serotonergic drugs may increase the risk of serotonin syndrome." [17]

The Natural Medicines Database rates the St. John's Wort and amphetamine interaction as "Moderate" severity, noting: "St. John's Wort can increase serotonin levels. Using it with amphetamines, which also increase serotonin, might cause too much serotonin in the body. This could result in serious side effects including heart problems, shivering, and anxiety." [18]

The FDA's guidance document on drug interactions and labeling specifically cites St. John's Wort as an example of an herbal inducer with the potential to reduce the efficacy of co-administered medications metabolized by CYP3A4, and recommends contraindication language where clinical significance is established [2].

A 2003 report in the British Medical Journal by Ernst documented 108 reported cases of herb-drug interactions with SJW submitted to pharmacovigilance systems across seven countries, placing it among the most interaction-prone herbal products in clinical use [19].

Recognizing Serotonin Syndrome Early

Knowing the early warning signs matters because mild serotonin toxicity is frequently misattributed to stimulant side effects.

Early Signs (Grade 1)

Akathisia (inner restlessness), mild tremor, diaphoresis, and mydriasis (dilated pupils) may appear within hours of adding a serotonergic agent. These symptoms overlap with amphetamine side effects, making the SJW contribution easy to miss.

Moderate Signs (Grade 2)

Hyperreflexia, clonus (rhythmic involuntary muscle contractions), tachycardia above 100 bpm at rest, and hyperthermia (temperature above 38.5°C / 101.3°F) indicate a more serious presentation requiring same-day medical evaluation.

Severe Signs (Grade 3)

Temperature above 41°C / 105.8°F, rhabdomyolysis, seizure, and cardiovascular instability define life-threatening serotonin syndrome. A 2003 paper by Boyer and Shannon in the New England Journal of Medicine remains the definitive clinical review of serotonin syndrome diagnosis and management and should be the primary reference for any clinician managing a suspected case [20].

Any patient on Vyvanse who adds SJW and then develops the Grade 1 signs listed above should stop the SJW, contact their prescriber the same day, and present to an emergency department if symptoms worsen within 2 to 4 hours.